News Focus

NINDS Delves Into Drug Development

See allHide authors and affiliations

Science  12 Jul 2002:
Vol. 297, Issue 5579, pp. 180
DOI: 10.1126/science.297.5579.180

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

The National Institute of Neurological Disorders and Stroke (NINDS) has traditionally left development of drugs for treating stroke, spinal cord injuries, and other neurological conditions largely up to the private sector. But NINDS will soon announce a dramatic departure from that policy: a new type of "translational" grant designed to bridge the gap between basic research and clinical trials.